GSK: malaria treatment gets positive results in phase III
(CercleFinance.com) - GSK announced the publication of positive results from a phase III study for the prevention of relapse of malaria in The New England Journal of Medicine.
A phase III study evaluating the efficacy of GSK's tafenoquine in 522 patients with P.vivax malaria from Ethiopia, Peru, Brazil, Cambodia, Thailand and the Philippines - met its primary endpoint.
Another study, conducted in 251 patients, showed less impressive results, with the incidence of decline in haemoglobin (the primary endpoint) very low and similar between treatment groups.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
A phase III study evaluating the efficacy of GSK's tafenoquine in 522 patients with P.vivax malaria from Ethiopia, Peru, Brazil, Cambodia, Thailand and the Philippines - met its primary endpoint.
Another study, conducted in 251 patients, showed less impressive results, with the incidence of decline in haemoglobin (the primary endpoint) very low and similar between treatment groups.
Copyright (c) 2019 CercleFinance.com. All rights reserved.